Literature DB >> 30196520

Biological variation of procalcitonin levels in hemodialysis patients.

Shun Kubo1, Masaki Iwasaki1, Mari Horie1, Ai Matsukane1, Toshihide Hayashi1, Yuri Tanaka1, Hiroki Hase1, Nobuhiko Joki2.   

Abstract

BACKGROUND: There is no obvious evidence regarding biological variation of procalcitonin (PCT) levels in hemodialysis (HD) patients without infections. The aim of this study was to determine the within- and between-person biological variation of PCT levels in HD patients without infections.
METHODS: A multicenter, prospective, cohort study enrolled 123 HD patients without any signs of infectious disease. Baseline PCT levels were determined pre- and post-HD, and then repeated pre-HD PCT measurements were performed at 2, 4, 8, 12, 16, 20, and 24 weeks after baseline blood-sampling, regardless of the presence or absence of infectious disease. Analytical variation (CVa), the within-person biological variation (CVi), between-person biological variation (CVb), individual index (II), and the reference change value (RCV) were calculated.
RESULTS: The mean age was 62.4 years, 76.4% were male, and 32.5% had diabetes. The mean duration of HD was 87 months. The median value for baseline pre-HD PCT was 0.23 ng/mL, which is much higher than the reference level for healthy individuals. PCT levels decreased of 46.6% after a single HD session. CVi was 24.9%, CVb was 54.2%, II was 0.46, and RCV was calculated as 96.4% with 99% probability.
CONCLUSIONS: The PCT level was significantly higher in stable HD patients without manifest bacterial infection. CVb was more variable than CVi in HD patients, which indicates that relative change is more important than absolute PCT levels for diagnosing bacterial infection, and doubling or more of the baseline PCT level may imply the presence of a bacterial infection in HD patients.

Entities:  

Keywords:  Bacterial infection; Dialysis membrane; Individual index; Procalcitonin; Reference change value

Mesh:

Substances:

Year:  2018        PMID: 30196520     DOI: 10.1007/s10157-018-1639-2

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  5 in total

Review 1.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

2.  Procalcitonin serum levels in stage 5 chronic kidney disease children on hemodialysis.

Authors:  Antoine Mouche; Cyrielle Parmentier; Claire Herbez Rea; Thérèsa Kwon; Olivia Boyer; Jean Daniel Delbet; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2021-03-17       Impact factor: 3.714

3.  A Remarkable Elevation in the Procalcitonin Levels Due to Diabetic Ketoacidosis in a Hemodialysis Patient.

Authors:  Shohei Fukunaga; Yuki Hoshino; Hirotaka Sonoda; Miharu Kawanishi; Asuka Yamauchi; Shiho Kato; Kaori Yoshikane; Hiroaki Shiina; Kazuaki Tanabe; Takafumi Ito
Journal:  Intern Med       Date:  2020-11-23       Impact factor: 1.271

4.  Diagnostic value of procalcitonin for bacterial infections in patients undergoing hemodialysis: a systematic review and meta-analysis.

Authors:  Mei Tao; Danna Zheng; Xudong Liang; Qiang He; Wei Zhang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 2.606

5.  The Sustained and Marked Elevation of Serum Procalcitonin in a Hemodialysis Patient with Tuberculous Lymphadenitis, but Without the Evidence of Sepsis: A Case Report.

Authors:  Peiyi Luo; Yanqiong Long; Liang Ma; Ye Tao; Shenju Gou
Journal:  Infect Drug Resist       Date:  2022-09-02       Impact factor: 4.177

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.